Up to 800 health centers were approved to administer Johnson & Johnson's ketamine depression drug, which was cleared for sale last month, and patients are already using it, the company said Tuesday.
In just over one month, J&J has confirmed up to 800 sites, implementing the company well for its plans for the year. earnings results. She said that some patients received their first dose, and some had received different doses.
“So we believe we have a very strong start with Spravato, and that it will be an important driver of growth,” she said.